Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-06, Stock:NVS, The news for the past five days is as follows:
2018-10-30: NEWS1: Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View.NEWS2: Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View.NEWS3: Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript.NEWS4: Sanofi’s Q3 Earnings: Analysts’ Estimates.NEWS5: Shire: Why Analysts Expect Revenue Growth in Q3 2018.
2018-10-31: NEWS1: Sandoz Receives FDA Approval For Biosimilar Hyrimoz.NEWS2: Sandoz Receives FDA Approval For Biosimilar Hyrimoz.NEWS3: GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript.NEWS4: Premier Bay Area biotech developer tees up next major project.NEWS5: Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View.NEWS6: Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View.NEWS7: Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag.NEWS8: Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag.NEWS9: Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag.NEWS10: FDA approves Novartis' copy of AbbVie bestseller Humira.NEWS11: Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View.NEWS12: Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line.NEWS13: Novartis May Beat Ironwood Pharmaceuticals to the Punch.NEWS14: Novartis May Beat Ironwood Pharmaceuticals to the Punch.NEWS15: Aging Blockbusters Send Amgen Inc.'s Bottom Line Lower.NEWS16: Aging Blockbusters Send Amgen Inc.'s Bottom Line Lower.NEWS17: Novartis May Beat Ironwood Pharmaceuticals to the Punch.NEWS18: Aging Blockbusters Send Amgen Inc.&apos;s Bottom Line Lower.
2018-11-01: NEWS1: Gene therapy: CHOP unveils $75M manufacturing facility (Photos).NEWS2: Call buyers take position in Novartis.NEWS3: Call buyers take position in Novartis.NEWS4: Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View.NEWS5: Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View.NEWS6: FDA Approves 3rd Humira Biosimilar, CLVS Tanks On Q3 Results, CRY On Watch.NEWS7: FDA Approves 3rd Humira Biosimilar, CLVS Tanks On Q3 Results, CRY On Watch.
2018-11-02: NEWS1: Novartis abandons effort for U.S. approval of biosimilar rituximab.NEWS2: Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology.NEWS3: AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up.NEWS4: AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up.NEWS5: Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates.NEWS6: Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates.NEWS7: Conatus&apos; (CNAT) Q3 Loss In Line, Revenues Lag Estimates.NEWS8: A Look at Merck’s Diabetes and Women’s Health Business.
2018-11-05: NEWS1: 4 months after drug approval, Achaogen eyes fire sale.NEWS2: Pre-Market Most Active for Nov 5, 2018 :  AAPL, GE, ACRX, CHK, TEVA, GGB, AMD, QQQ, SQQQ, LYG, NVS, TQQQ.NEWS3: Pre-Market Most Active for Nov 5, 2018 :  AAPL, GE, ACRX, CHK, TEVA, GGB, AMD, QQQ, SQQQ, LYG, NVS, TQQQ.NEWS4: Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021.NEWS5: Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021.

Answer: Decrease